Senate Dem to block Obama's FDA nominee

Senate Dem to block Obama's FDA nominee
© Getty Images

Sen. Edward MarkeyEdward (Ed) John MarkeyOvernight Regulation: FTC launches probe into Equifax | Dems propose tougher data security rules | NYC aims to slash greenhouse gas emissions | EPA to reconsider Obama coal ash rule Overnight Cybersecurity: Kaspersky to testify before House | US sanctions Iranians over cyberattacks | Equifax reveals flaw that led to hack Dems propose data security bill after Equifax hack MORE (D-Mass.) says he's blocking the nomination of Dr. Robert Califf to be commissioner of the Food and Drug Administration until the agency makes reforms to its approval process for opioid painkillers.

Markey said Monday he put a hold on Califf, whose nomination cleared the Senate Health Committee earlier this month and was headed to the floor for a vote.

ADVERTISEMENT
Markey is upset with the FDA’s decision last year to approve the use of OxyContin to treat children as young as 11 years old. He called on the agency to commit to holding advisory committees before approving such painkillers in the future.

“While people in every community across the country are dying every day from opioid overdoses, the FDA continues to operate as if safety just means the right dose when it should include all the dangers of these painkillers,” he said in a statement.

“Expert after expert has warned about the real world dangers of abuse of and dependence on these new supercharged opioid painkillers, but the FDA has willfully blinded itself to the warning signs.

In October, Sen. Bernie SandersBernard (Bernie) SandersOvernight Defense: Senate passes 0B defense bill | 3,000 US troops heading to Afghanistan | Two more Navy officials fired over ship collisions Senate passes 0B defense bill Dems fear lasting damage from Clinton-Sanders fight MORE (I-Vt.), a Democratic presidential candidate, announced he would oppose Califf's nomination over concerns that the cardiologist and longtime Duke University researcher has close ties to the drug industry.